Post-Closing M&A Claims and Purchase Price Adjustments: Where Do They Stand Heading Into 2023?
Deal Terms Analysis
2022 PE-Buyer Deal Terms
Deal Terms Analysis
How M&A Advisors Use Deal Data to Improve the Due Diligence Process
Deal Terms Analysis
2022 M&A Deal Terms Study Update with Key Findings
Deal Terms Analysis
2022 M&A Claims Insights Report
Deal Terms Analysis
2022 Technology M&A Deals Special Report
Deal Terms Analysis
2022 M&A Deal Terms Study
Deal Terms Analysis
2021 Life Sciences M&A Study
Deal Terms Analysis
2020 M&A Claims Insights Report
Deal Terms Analysis
What to Make of the Great Hill Case – The M&A Bar is Not Yet in Agreement on How Best to Address Merger Agreement Privilege Issues
Deal Terms Analysis
2020 Review: COVID-19 Impact on M&A Transactions
Deal Terms Analysis
M&A Deal Terms & Trends Pre- & Post-COVID-19
Deal Terms Analysis
M&A: Who Owns the Attorney-Client Privilege After Closing?
Deal Terms Analysis
2020 Buy-Side Reps and Warranties Insurance Deal Terms Update
Deal Terms Analysis
A First Look at the Impacts of Coronavirus on M&A Transactions
Deal Terms Analysis
Life Sciences: Milestone Trends by Product Stage
Deal Terms Analysis
Life Sciences: Timeline of Milestone Payments
Deal Terms Analysis
Addressing Target Company Privilege in Merger Agreements Five Years after Great Hill v. SIG
Deal Terms Analysis
Beware of Exclusions When Defining Net Working Capital in M&A Transactions
Deal Terms Analysis
2019 Life Sciences Study Quick Reference Guide
Deal Terms Analysis
2019 Life Sciences M&A Study
Deal Terms Analysis
2018 M&A Claims Insights Report
Deal Terms Analysis
Understanding Changes in Shareholder Consent Requirements
Deal Terms Analysis
Impact of “Buyer Power Ratio” on M&A Deal Terms
Deal Terms Analysis
Clarifying When Attorneys’ Fees Constitute Damages
Deal Terms Analysis
M&A Conflict Waivers
Deal Terms Analysis
Do Carveouts to Caps Work the Way You Intend?
Deal Terms Analysis
Definition of Purchase Price
© 2024 SRS Acquiom Inc.
